Prolongation of survival and improvement in performance status following palliative chemotherapy in gastrointestinal cancer patients with a poor performance status

Oncology

Volumn 74, Issue 3-4, 2008, Pages 135-142

  Shitara, Kohei ^a,b   Munakata, Masaki ^a   Kasai, Masaharu ^a   Muto, Osamu ^a   Sakata, Yuh ^a  

^a Misawa City Hospital   (Japan)

^b Misawa City Hospital   (Japan)

Author keywords

Chemotherapy; Gastrointestinal cancer; Palliative chemotherapy; Performance status, poor

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; STARCH MICROSPHERE; TUMOR MARKER;

ADULT; AGED; ANEMIA; ANOREXIA NERVOSA; ARTICLE; ASCITES; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG FATALITY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PANCREAS CANCER; PATIENT ASSESSMENT; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 49549109590     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151360     Document Type: Article

References (23)

1. Buonadonna A, Lombardi D, De Paoli A, Bidoli E, Frustaci S: Adenocarcinoma of the stomach: univariate and multivariate analyses of factors associated with survival. Suppl Tumori 2003;2:S31-S34.
2. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403.
3. Mitry E, Douillard JY, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P: Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-1017.
4. Boeck S, Hinke A, Wilkowski R, Heinemann V: Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007;13:224-227.
5. Saisho T, Okusaka T, Ueno H, Morizane C, Okada S: Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Hepatogastroenterology 2005;52:1654-1658.
6. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S, Steering Committee of the European Association for Palliative Care: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240-6248.
7. Tassinari D, Montanari L, Maltoni M, Ballardini M, Piancastelli A, Musi M, Porzio G, Minotti V, Caraceni A, Poggi B, Stella A, Aielli F, Scarpi E: The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. Support Care Cancer 2008;16:359-370.
8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
9. Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky Performance Status Scale: An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-2007.
10. de Gramont A, Porschen R, Saltz L, Rougier P, Tournigand C, Grothey A, Sargent DJ: A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC) (abstract 4011). Annual Meeting of the American Society of Clinical Oncology, Chicago, 2007.
11. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-1268.
12. Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC: A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 2007;97:458-463.
13. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL: Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology 1997;54:275-280.
14. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. NCCNR Practice Guidelines in Oncology, version 1.2008.
15. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. NCCNR Practice Guidelines in Oncology, version 2.2007.
16. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. NCCNR Practice Guidelines in Oncology, version 1.2008.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
18. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, ed 13 (in Japanese). Tokyo, Kanehara, 1998.
19. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
20. Fujimoto-Ouchi K, Onuma E, Shirane M, Mori K: Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother Pharmacol 2007;59:807-815.
21. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132-138.
22. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA: Serum CA 19-9 response as a surrogate marker for clinical outcome in patients receiving fixed dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195-199.
23. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V: Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255-264.